Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LL-RP-GD
- Development stage
- Discontinued
- Lead developer
- Xinjiang University
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intranasal
01
Overview
LL-RP-GD is a recombinant strain of the food-grade bacterium *Lactococcus lactis* NZ3900, engineered to serve as a dual-reporter control vector in mucosal vaccine and gene therapy research. It contains two distinct expression systems: a prokaryotic cassette (P32 promoter) for the constitutive expression of Red Fluorescent Protein (RFP) and a eukaryotic expression cassette for the delivery of enhanced Green Fluorescent Protein (eGFP) DNA to mammalian cells. Developed by researchers at Xinjiang University, LL-RP-GD is primarily utilized as a negative control in studies evaluating therapeutic lactococcal vaccines, such as those targeting HPV-16 E7. It allows researchers to account for the baseline immunogenicity of the *L. lactis* vector and verify the successful co-delivery of both protein and DNA payloads to mucosal surfaces via intranasal administration.
- Other names
- Lactococcus lactis RP-GDLL-RFP-eGFP
02
Targets
DNA
Beyond the preview
Go deeper on LL-RP-GD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LL-RP-GD.